Recruiting
Phase 2

Reduced Intensity Conditioning

Sponsor:

Paul Szabolcs

Code:

NCT01962415

Conditions

Primary Immunodeficiency (PID)

Congenital Bone Marrow Failure Syndromes

Inherited Metabolic Disorders (IMD)

Hereditary Anemias

Inflammatory Conditions

Eligibility Criteria

Sex: All

Age: 0 - 55

Healthy Volunteers: Not accepted

Interventions

Hydroxyurea

Alemtuzumab

Fludarabine

Melphalan

Thiotepa

Study Details

Brief summary:

The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant (BMT) or peripheral blood stem cell transplant (PBSCT) in patients with non-malignant disorders that are amenable to treatment with hematopoietic stem cell transplant (HSCT). After transplant, subjects will be followed for late effects and for ongoing graft success.

Conditions

Primary Immunodeficiency (PID)

Congenital Bone Marrow Failure Syndromes

Inherited Metabolic Disorders (IMD)

Hereditary Anemias

Inflammatory Conditions

Study ID

NCT01962415

Start date

Feb 4, 2014

Status verified date

Dec, 2025

Completion date

Nov, 2027

Anticipated

Primary completion date

Nov, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0 - 55

Healthy Volunteers: Not accepted

Inclusion:

1. A 4/6, 5/6 or 6/6 HLA matched related or unrelated UCB unit available that will deliver a pre-cryopreservation total nucleated cell dose of ≥ 3 x 10e7 cells/kg, or double unit grafts, each cord blood unit delivering at least 2 x 10e7 cells/kg OR an 8 of 8 or 7 of 8 HLA allele level matched unrelated donor bone marrow or peripheral blood progenitor graft.
2. Adequate organ function as measured by:

1. Creatinine ≤ 2.0 mg/dL and creatinine clearance ≥ 50 mL/min/1.73 m2.
2. Hepatic transaminases (ALT/AST) ≤ 4 x upper limit of normal (ULN).
3. Adequate cardiac function by echocardiogram or radionuclide scan (shortening fraction > 26% or ejection fraction > 40% or > 80% of normal value for age).
4. Pulmonary evaluation testing demonstrating CVC or FEV1/FVC of ≥ 50% of predicted for age and/or resting pulse oximeter ≥ 92% on room air or clearance by the pediatric or adult pulmonologist. For adult patients DLCO (corrected for hemoglobin) should be ≥ 50% of predicted if the DLCO can be obtained.
3. Written informed consent and/or assent according to FDA guidelines.
4. Negative pregnancy test if pubertal and/or menstruating.
5. HIV negative.
6. A non-malignant disorder amenable to treatment by stem cell transplantation, including but not limited to:

1. Primary Immunodeficiency syndromes including but not limited to:

  • Severe Combined Immune Deficiency (SCID) with NK cell activity
  • Omenn Syndrome
  • Bare Lymphocyte Syndrome (BLS)
  • Combined Immune Deficiency (CID) syndromes
  • Combined Variable Immune Deficiency (CVID) syndrome
  • Wiskott-Aldrich Syndrome
  • Leukocyte adhesion deficiency
  • Chronic granulomatous disease (CGD)
  • X-linked Hyper IgM (XHIM) syndrome
  • IPEX syndrome
  • Chediak - Higashi Syndrome
  • Autoimmune Lymphoproliferative Syndrome (ALPS)
  • Hemophagocytic Lymphohistiocytosis (HLH) syndromes
  • Lymphocyte Signaling defects
  • Other primary immune defects where hematopoietic stem cell transplantation may be beneficial
2. Congenital bone marrow failure syndromes including but not limited to:

  • Dyskeratosis Congenita (DC)
  • Congenital Amegakaryocytic Thrombocytopenia (CAMT)
  • Osteopetrosis
3. Inherited Metabolic Disorders (IMD) including but not limited to:

  • Mucopolysaccharidoses

  • Hurler syndrome (MPS I)
  • Hunter syndrome (MPS II)
  • Leukodystrophies

  • Krabbe Disease, also known as globoid cell leukodystrophy
  • Metachromatic leukodystrophy (MLD)
  • X-linked adrenoleukodystrophy (ALD)
  • Hereditary diffuse leukoencephalopathy with spheroids (HDLS)
  • Other inherited metabolic disorders

  • alpha mannosidosis
  • Gaucher Disease
  • Other inheritable metabolic diseases where hematopoietic stem cell transplantation may be beneficial.
4. Hereditary anemias

  • Thalassemia major
  • Sickle cell disease (SCD) - patients with sickle disease must have one or more of the following:

  • Overt or silent stroke
  • Pain crises ≥ 2 episodes per year for past year
  • One or more episodes of acute chest syndrome
  • Osteonecrosis involving ≥ 1 joints
  • Priapism
  • Diamond Blackfan Anemia (DBA)
  • Other congenital transfusion dependent anemias
5. Inflammatory Conditions

  • Crohn's Disease/Inflammatory Bowel Disease

Exclusion:

1. Allogeneic hematopoietic stem cell transplant within the previous 6 months.
2. Any active malignancy or MDS.
3. Severe acquired aplastic anemia.
4. Uncontrolled bacterial, viral or fungal infection (currently taking medication and with progression of clinical symptoms).
5. Pregnancy or nursing mother.
6. Poorly controlled pulmonary hypertension.
7. Any condition that precludes serial follow-up.

Study Design

Enrollment

100 participants

Anticipated

Allocation

Non randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: UCBT:transfusion dependent anemias or increased rejection risk

Alemtuzumab, Hydroxyurea, Fludarabine, Melphalan, and Thiotepa conditioning regimen prior to allogenic HSCT.

experimental: BMT, PBSCT and not transfusion dependent UCBT

Alemtuzumab, Hydroxyurea, Fludarabine, Melphalan, and Thiotepa conditioning regimen prior to allogenic HSCT.

Interventions

Hydroxyurea

Oral administration

Alemtuzumab

Intravenous (IV) administration.

Fludarabine

IV administration

Melphalan

IV administration

Thiotepa

IV administration

Primary outcome measure

  • Post-transplant treatment-related mortality (TRM) [ Time Frame: 1 year post-transplant ]
  • Neurodevelopmental milestones [ Time Frame: 1 year post-transplant ]
  • Immune Reconstitution [ Time Frame: 1 year post-transplant ]
  • Severe opportunistic infections [ Time Frame: 1 year post-transplant ]
  • GVHD occurrence [ Time Frame: 1 year post-transplant ]

Central Contacts and Locations

Central contacts

Locations

UPMC Children's Hospital of Pittsburgh

Recruiting

Pittsburgh, Pennsylvania, United States, 15224

Contacts

More Information

Sponsor

Paul Szabolcs

Last update posted

Dec 15, 2025

Last verified

Dec, 2025

Keywords

  • Severe Combined Immune Deficiency (SCID)
  • Omenn Syndrome
  • Bare Lymphocyte Syndrome (BLS)
  • Combined Immune Deficiency (CID) syndromes
  • Combined Variable Immune Deficiency (CVID) syndrome
  • Wiskott-Aldrich Syndrome
  • Leukocyte adhesion deficiency
  • Chronic granulomatous disease (CGD)
  • X-linked Hyper IgM (XHIM) syndrome
  • IPEX syndrome
  • Chediak - Higashi Syndrome
  • Autoimmune Lymphoproliferative Syndrome (ALPS)
  • Hemophagocytic Lymphohistiocytosis (HLH) syndromes
  • Lymphocyte Signaling defects
  • Dyskeratosis Congenita (DC)
  • Congenital Amegakaryocytic Thrombocytopenia (CAMT)
  • Osteopetrosis
  • Mucopolysaccharidoses
  • Hurler syndrome (MPS I)
  • Hunter syndrome (MPS II)
  • Leukodystrophies
  • Krabbe Disease
  • Metachromatic leukodystrophy (MLD)
  • X-linked adrenoleukodystrophy (ALD)
  • Alpha mannosidosis
  • Gaucher Disease
  • Thalassemia major
  • Sickle cell disease (SCD)
  • Diamond Blackfan Anemia (DBA)
  • Crohn's Disease
  • Inflammatory Bowel Disease
  • Hematopoietic Stem Cell Transplant (HSCT)
  • Congenital transfusion dependent anemias
  • Globoid cell leukodystrophy
  • Hereditary diffuse leukoencephalopathy with spheroids (HDLS)
  • Systemic Juvenile Idiopathic Arthritis (sJIA)
  • Juvenile Rheumatoid Arthritis (JRA)

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Paul Szabolcs on 2025-12-15.